Previous 10 | Next 10 |
Gainers: Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. Outset Medical (NASDAQ:OM) +10%. Masimo (NASDAQ:MASI) +8%. Vivos Therapeutics (NASDAQ:VVOS) +7%. Losers: 10x Genomics (NASDAQ:TXG) -16%. iSpecimen ISPC -10%. Poseida ...
Marin Software (NASDAQ:MRIN) +25% on TikTok integration in platform. DoorDash (NYSE:DASH) +24% on Q4 results. Global-e Online (NASDAQ:GLBE) +15% on Q4 results. TriNet (NYSE:TNET) +9% commences a modified dutch auction tender offer to repurchase up to $300M o...
-- Patients with BBS achieved deepened and sustained weight loss at 24 months on setmelanotide therapy -- -- Company to provide update on U.S. BBS commercial readiness during virtual event today at 4 p.m. ET -- BOSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceutica...
-- Key opinion leaders and patient caregiver to discuss patient experience -- -- Company to provide update on U.S. BBS commercial readiness during event for investors and analysts -- -- Prescription Drug User Fee Act (PDUFA) goal date for setmelanotide for patients w...
-- DAYBREAK is the most comprehensive Phase 2 trial ever initiated in rare genetic diseases of obesity -- -- DAYBREAK is evaluating setmelanotide in patients with severe obesity and hyperphagia caused by variants in one of 31 pre-identified genes -- -- First patient also dosed...
Rhythm Pharmaceuticals (NASDAQ:RYTM) announces an exclusive licensing agreement with and China-based RareStone LTD, for the development and commercialization of Imcivree (setmelanotide) in China, including mainland China, Hong Kong and Macau. According to the terms of the agreement, RareStone...
-- RareStone to seek marketing authorization for IMCIVREE to treat obesity due to biallelic POMC, PCSK1 and LEPR deficiencies and Bardet-Biedl and Alström syndromes in mainland China, Hong Kong and Macau -- -- Rhythm to receive $12 million upfront in cash and equity, up to $63....
Rhythm Pharmaceuticals (NASDAQ:RYTM) has added ~5.4% in the pre-market after announcing that the FDA accepted the company’s supplemental New Drug Application ((sNDA)) for IMCIVREE (setmelanotide) for Bardet-Biedl syndrome (BBS) or Alström syndrome. The regulator has...
BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that the U.S. Food and Drug Administration (FDA) h...
BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Exe...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...